Compare CellSource Co., Ltd. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 16.13%
2
Company has very low debt and has enough cash to service the debt requirements
3
The company has declared Negative results for the last 6 consecutive quarters
4
With ROE of 0.64%, it has a expensive valuation with a 2.28 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 8,503 Million (Micro Cap)
357.00
NA
0.00%
-0.78
0.84%
1.41
Revenue and Profits:
Net Sales:
860 Million
(Quarterly Results - Jan 2026)
Net Profit:
34 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.51%
0%
-0.51%
6 Months
-31.94%
0%
-31.94%
1 Year
-50.82%
0%
-50.82%
2 Years
-71.72%
0%
-71.72%
3 Years
-88.31%
0%
-88.31%
4 Years
-85.59%
0%
-85.59%
5 Years
-89.66%
0%
-89.66%
CellSource Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.65%
EBIT Growth (5y)
-173.68%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0.73
Tax Ratio
58.23%
Dividend Payout Ratio
929.37%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
115.51%
ROE (avg)
16.13%
Valuation key factors
Factor
Value
P/E Ratio
357
Industry P/E
Price to Book Value
2.28
EV to EBIT
-66.17
EV to EBITDA
304.89
EV to Capital Employed
5.64
EV to Sales
2.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.52%
ROE (Latest)
0.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jan'26 - QoQ
Jan'26
Oct'25
Change(%)
Net Sales
860.00
893.40
-3.74%
Operating Profit (PBDIT) excl Other Income
103.40
99.50
3.92%
Interest
0.30
0.20
50.00%
Exceptional Items
-6.20
-47.90
87.06%
Consolidate Net Profit
33.60
-75.60
144.44%
Operating Profit Margin (Excl OI)
69.30%
48.50%
2.08%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jan 2026 is -3.74% vs -10.45% in Oct 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jan 2026 is 144.44% vs -200.67% in Oct 2025
Annual Results Snapshot (Consolidated) - Oct'25
Oct'25
Oct'24
Change(%)
Net Sales
3,711.50
4,355.10
-14.78%
Operating Profit (PBDIT) excl Other Income
371.00
282.40
31.37%
Interest
1.30
1.40
-7.14%
Exceptional Items
-38.20
10.20
-474.51%
Consolidate Net Profit
10.70
237.90
-95.50%
Operating Profit Margin (Excl OI)
44.90%
29.70%
1.52%
USD in Million.
Net Sales
YoY Growth in year ended Oct 2025 is -14.78% vs -3.45% in Oct 2024
Consolidated Net Profit
YoY Growth in year ended Oct 2025 is -95.50% vs -74.23% in Oct 2024
About CellSource Co., Ltd. 
CellSource Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






